Your browser doesn't support javascript.
loading
Insulin-like peptide 5 is an orexigenic gastrointestinal hormone.
Grosse, Johannes; Heffron, Helen; Burling, Keith; Akhter Hossain, Mohammed; Habib, Abdella M; Rogers, Gareth J; Richards, Paul; Larder, Rachel; Rimmington, Debra; Adriaenssens, Alice A; Parton, Laura; Powell, Justin; Binda, Matteo; Colledge, William H; Doran, Joanne; Toyoda, Yukio; Wade, John D; Aparicio, Samuel; Carlton, Mark B L; Coll, Anthony P; Reimann, Frank; O'Rahilly, Stephen; Gribble, Fiona M.
Afiliação
  • Grosse J; Takeda Cambridge Ltd., Cambridge CB4 0PA, United Kingdom;
  • Heffron H; Takeda Cambridge Ltd., Cambridge CB4 0PA, United Kingdom;
  • Burling K; Core Biochemical Assay Laboratory, Addenbrooke's Hospital, Cambridge CB2 0QQ, United Kingdom;
  • Akhter Hossain M; Florey Institute of Neuroscience and Mental Health, and School of Chemistry, University of Melbourne, Melbourne, VIC 3010, Australia;
  • Habib AM; Cambridge Institute for Medical Research, University of Cambridge, Cambridge CB2 0XY, United Kingdom;
  • Rogers GJ; Cambridge Institute for Medical Research, University of Cambridge, Cambridge CB2 0XY, United Kingdom;
  • Richards P; Cambridge Institute for Medical Research, University of Cambridge, Cambridge CB2 0XY, United Kingdom;Metabolic Research Laboratories and MRC Metabolic Diseases Unit, Institute of Metabolic Science, University of Cambridge, Cambridge CB2 0QQ, United Kingdom;
  • Larder R; Metabolic Research Laboratories and MRC Metabolic Diseases Unit, Institute of Metabolic Science, University of Cambridge, Cambridge CB2 0QQ, United Kingdom;
  • Rimmington D; Metabolic Research Laboratories and MRC Metabolic Diseases Unit, Institute of Metabolic Science, University of Cambridge, Cambridge CB2 0QQ, United Kingdom;
  • Adriaenssens AA; Cambridge Institute for Medical Research, University of Cambridge, Cambridge CB2 0XY, United Kingdom;Metabolic Research Laboratories and MRC Metabolic Diseases Unit, Institute of Metabolic Science, University of Cambridge, Cambridge CB2 0QQ, United Kingdom;
  • Parton L; Takeda Cambridge Ltd., Cambridge CB4 0PA, United Kingdom;
  • Powell J; Takeda Cambridge Ltd., Cambridge CB4 0PA, United Kingdom;
  • Binda M; Frimorfo Ltd., 1723 Fribourg, Switzerland;
  • Colledge WH; Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge CB2 3EG, United Kingdom;
  • Doran J; Takeda Cambridge Ltd., Cambridge CB4 0PA, United Kingdom;
  • Toyoda Y; Takeda Pharmaceutical Co. Ltd., Osaka, Japan; and.
  • Wade JD; Florey Institute of Neuroscience and Mental Health, and School of Chemistry, University of Melbourne, Melbourne, VIC 3010, Australia;
  • Aparicio S; British Columbia Cancer Agency Branch, Vancouver, Canada V5Z 1L3.
  • Carlton MB; Takeda Cambridge Ltd., Cambridge CB4 0PA, United Kingdom;
  • Coll AP; Metabolic Research Laboratories and MRC Metabolic Diseases Unit, Institute of Metabolic Science, University of Cambridge, Cambridge CB2 0QQ, United Kingdom;
  • Reimann F; Cambridge Institute for Medical Research, University of Cambridge, Cambridge CB2 0XY, United Kingdom;Metabolic Research Laboratories and MRC Metabolic Diseases Unit, Institute of Metabolic Science, University of Cambridge, Cambridge CB2 0QQ, United Kingdom;
  • O'Rahilly S; Metabolic Research Laboratories and MRC Metabolic Diseases Unit, Institute of Metabolic Science, University of Cambridge, Cambridge CB2 0QQ, United Kingdom; so104@medschl.cam.ac.uk.
  • Gribble FM; Cambridge Institute for Medical Research, University of Cambridge, Cambridge CB2 0XY, United Kingdom;Metabolic Research Laboratories and MRC Metabolic Diseases Unit, Institute of Metabolic Science, University of Cambridge, Cambridge CB2 0QQ, United Kingdom;
Proc Natl Acad Sci U S A ; 111(30): 11133-8, 2014 Jul 29.
Article em En | MEDLINE | ID: mdl-25028498
The gut endocrine system is emerging as a central player in the control of appetite and glucose homeostasis, and as a rich source of peptides with therapeutic potential in the field of diabetes and obesity. In this study we have explored the physiology of insulin-like peptide 5 (Insl5), which we identified as a product of colonic enteroendocrine L-cells, better known for their secretion of glucagon-like peptide-1 and peptideYY. i.p. Insl5 increased food intake in wild-type mice but not mice lacking the cognate receptor Rxfp4. Plasma Insl5 levels were elevated by fasting or prolonged calorie restriction, and declined with feeding. We conclude that Insl5 is an orexigenic hormone released from colonic L-cells, which promotes appetite during conditions of energy deprivation.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Colo / Células Enteroendócrinas / Hormônios Peptídicos / Ingestão de Alimentos Limite: Animals / Female / Humans / Male Idioma: En Revista: Proc Natl Acad Sci U S A Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Colo / Células Enteroendócrinas / Hormônios Peptídicos / Ingestão de Alimentos Limite: Animals / Female / Humans / Male Idioma: En Revista: Proc Natl Acad Sci U S A Ano de publicação: 2014 Tipo de documento: Article